In a slightly unconventional deal, New York-based HiberCell is leveraging a chunk of its stock — still privately owned — to buy out Genuity Science and its suite of tools for genomics and multi-omic analytics, as well as an AI and machine learning platform.nnPraxis highlighted a small cut of Phase IIa study results Monday morning for their up and coming perimenopausal depression program.
Praxis is proud to announce to be the recipient of a Fast-Track SBIR award to develop treatment for apathy in Alzheimer’s Disease. The award, in its second of three years and expected to total $2.9 million, will support the IND-enabling work to advance the Company’s lead candidate, PRX-P4-003, a novel dopaminergic stimulant prodrug for the treatment of apathy in AD.
SACRAMENTO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic central nervous system disorders, today announced that it has successfully completed a microdose study in healthy volunteers under an exploratory IND approved by FDA in January 2021.
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that the U.S. Food and Drug Administration (FDA) has granted both rare pediatric disease and orphan drug designations for PRAX-222 for the treatment of SCN2A developmental and epileptic encephalopathy (SCN2A-DEE). The FDA has also granted rare pediatric disease designation for PRAX-562 for the treatment of SCN2A-DEE and for the treatment of SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).
2020 is turning out to be a big year for Praxis Precision Medicines. After launching in May with $100 million, the CNS-focused biotech wasted no time topping up its coffers with another $110 million. Now, it’s pulled off a $190 million IPO, upgrading from the $100 million listing it originally sought in September and the revised goal of $175 it set on Thursday.